Recent approaches in acute lymphoblastic leukemia in adults

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 2, 2002, Pages 114-141

  Gökbuget, Nicola ^a   Hoelzer, Dieter ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EXAMINATION; HUMAN; LABORATORY DIAGNOSIS; MINIMAL RESIDUAL DISEASE; PROGNOSIS; RELAPSE; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; CLASSIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; RISK ASSESSMENT;

EID: 0036341295     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00068.x     Document Type: Review

References (116)

1. Proposals for classification of acute leukaemias
2. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
3. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 8364
4. Immunophenotypic features of childhood and adult Acute Lymphoblastic Leukemia (ALL). Experience of the German Multicentre Trials ALL-BFM and GMALL
5. Proposal for the immunological classification of acute leukemias
6. Immunophenotypic classification of acute lymphoblastic leukemia
7. Prospective karyotype analysis in adult acute lymphoblastic leukemia. The Cancer Leukemia Group B Experience
8. Age distribution of good and poor risk chromosomal sub-groups among the first 1500 cases in the LRF UKCCG karyotype database in acute lymphoblastic leukaemia
9. Cytogenetic abnormalities in adult lymphoblastic leukemia: Correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogénétique Hématologique
10. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia
11. Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan
12. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia
13. TEL-AML1 fusion in acute lymphoblastic leukemia of adults
14. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, 16, 18 and p19 in human leukemia-lymphoma cells
15. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia
16. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15 (INK4b)/p16 (INK4a)/p14 (ARF) in patients with acute lymphoblastic leukemia
17. Acquisition of p16 (INK4A) and p15 (INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia
18. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood
19. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia
20. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase
21. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
22. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
23. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
24. Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance
25. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89)
26. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia. CALGB Study 9111
27. High dose ara-c as upfront therapy for adult patients with acute lymphoblastic leukemia (ALL)
28. Results of treatment with hyper-CVAD, a doseintensive regimen, in adult acute lymphocytic leukemia
29. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups
30. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin
31. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84)
32. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87
33. Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research council randomized trial UKALL XA
34. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from the international ALL trial (MRC UKALL/ECOG E2993)
35. Intensification of induction and consolidation improves only subgroups of adult. ALL Anal 1200 Patients GMALL Study 05/93
36. Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study
37. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
38. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
39. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: First results from a phase II clinical study
40. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811
41. Acute lymphoblastic leukemia in adults
42. The role of anthracyclines in adult acute lymphoblastic leukemia
43. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia
44. Intensified and shortened chemotherapy for adult acute lymphoblastic leukemia
45. Induction therapy with dose-escalated adriamycin and four other drugs, followed by intensive consolidation and maintenance therapy for adult ALL. The JALSG All93 Study
46. Interim analysis of the GIMEMA ALL0496 trial for adult acute lymphoblastic leukemia (ALL)
47. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia
48. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia
49. PEG L-asparaginase (PEG-ASNase) containing chemotherapy in untreated acute lymphoblastic leukemia adults
50. Effectivity and toxicity of PEG-L-Asparaginase as part of a multidrug induction regimen in a multicenter trial in adult ALL
51. Therapy of adult ALL: Overview of 2 successive EORTC studies: (ALL-2 ALL-3)
52. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma
53. Cytarabine with high-dose motixantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone
54. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia GOELAMS Group
55. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period
56. Adult acute lymphocytic leukemia: The Eastern Cooperative Oncology Group experience
57. Induction therapy of adult acute lymphoblastic leukemia without the use of vincristine or prednisone
58. Autologous bone marrow transplantation in acute myeloid leukemia in first remission
59. High efficiency of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastiac leukemia (ALL) - A single institution study
60. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial
61. New approaches in acute lymphoblastic leukemia in adults: Where do we go?
62. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction: Preliminary results on 66 patients
63. Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL)
64. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study
65. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
66. International Childhood Acute Lymphoblastic Leukemia Workshop. Sausalito, CA, 30 November - 1 December 2000
67. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group
68. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
69. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
70. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone. A CALGB study
71. Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: A pilot assessment
72. The GIMEMA ALL 0183 trial: Analysis of 10-year follow-up
73. Recent approaches in acute lymphoblastic leukemia in adults
74. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation
75. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome
76. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation
77. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow-transplantation
78. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement
79. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia (AL) in first complete remission
80. Autologous bone marrow transplantation or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 Cases from a single center
81. Meningeosis leukaemica in adult acute lymphoblastic leukemia
82. Characteristics and outcome of CNS relapse in patients with acute lymphoblastic leukemia (ALL)
83. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL)
84. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncol Group (POG) Study
85. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia
86. Intensified chemotherapy and mediastinal irradiation in adult T-cell acute lymphoblastic leukemia
87. Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: Initial observations
88. A phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies
89. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
90. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia
91. The effect of anti-B4-blocked Ricin (anti-B4-BR) on minimal residual disease (MRD) in adults with B-lineage acute lymphoblastic leukemia (ALL) (CALGB 9311,8762,8763)
92. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
93. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implications for treatment of infants
94. Pre-pre-B acute lymphoblastic leukemia: High frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission
95. Improved outcome in adult B-cell acute lymphoblastic leukemia
96. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
97. The impact of age on outcome in lymphoblastic leukemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties
98. Subtypes and treatment outcome in adult acute lymphoblastic leukemia (ALL) < > 55 yrs
99. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
100. The Philadelphia chromosome t(9; 22) is associated with in vitro prednisolone and daunorubicin resistance in adult acute lymphoblastic leukemia
101. Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia
102. Multidrug resistance proteins MDR1/P-gp, MRP1 and LRP in adult ALL patients uniformly treated according to the GIMEMA 0496 protocol: Poor prognostic impact of MDR1/P-gp
103. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
104. Prognostic value of immunophenotypic detection of minimal residual disease in acute lyphoblastic leukemia
105. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome
106. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood
107. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
108. Rapid molecular response during early induction chemotherapy predicts good outcome in childhood acute lymphoblastic leukemia
109. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia
110. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia
111. Minimal residual disease in adult patients with acute lymphoblastic leukemia during the first year of therapy predicts clinical outcome
112. Risk stratification in childhood acute lymphoblastic leukemia based on clone-specific detection of minimal residual disease (MRD) with molecular genetics: Performance in German Trial ALL-BFM 2000
113. Clinical impact of minimal residual disease (MRD) in trial design for adult ALL
114. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
115. The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia
116. Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy